Innovation Pharmaceuticals Stock Performance
| IPIX Stock | USD 0 0.0003 42.86% |
Innovation Pharmaceuticals holds a performance score of 10 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 6.72, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Innovation Pharmaceuticals will likely underperform. Use Innovation Pharmaceuticals maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Innovation Pharmaceuticals.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Innovation Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak forward indicators, Innovation Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 10.2 M | |
| Total Cashflows From Investing Activities | -4.1 M | |
| Free Cash Flow | -6.4 M |
Innovation |
Innovation Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.10 in Innovation Pharmaceuticals on October 30, 2025 and sell it today you would earn a total of 0.00 from holding Innovation Pharmaceuticals or generate 0.0% return on investment over 90 days. Innovation Pharmaceuticals is currently generating 5.7064% in daily expected returns and assumes 42.1666% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Innovation, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Innovation Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Innovation Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0 | 90 days | 0 | about 30.52 |
Based on a normal probability distribution, the odds of Innovation Pharmaceuticals to move above the current price in 90 days from now is about 30.52 (This Innovation Pharmaceuticals probability density function shows the probability of Innovation Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 6.72 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Innovation Pharmaceuticals will likely underperform. In addition to that Innovation Pharmaceuticals has an alpha of 5.0097, implying that it can generate a 5.01 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Innovation Pharmaceuticals Price Density |
| Price |
Predictive Modules for Innovation Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Innovation Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Innovation Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Innovation Pharmaceuticals is not an exception. The market had few large corrections towards the Innovation Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Innovation Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Innovation Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 5.01 | |
β | Beta against Dow Jones | 6.72 | |
σ | Overall volatility | 0.0003 | |
Ir | Information ratio | 0.13 |
Innovation Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Innovation Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Innovation Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Innovation Pharmaceuticals is way too risky over 90 days horizon | |
| Innovation Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Innovation Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Innovation Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Innovation Pharmaceuticals currently holds 1.24 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Innovation Pharmaceuticals has a current ratio of 0.59, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation to invest in growth at high rates of return. When we think about Innovation Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 18 K. Net Loss for the year was (7.04 M) with profit before overhead, payroll, taxes, and interest of 18 K. | |
| Innovation Pharmaceuticals currently holds about 2.97 M in cash with (6.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Innovation Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Innovation Pink Sheet often depends not only on the future outlook of the current and potential Innovation Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Innovation Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 472.2 M | |
| Short Long Term Debt | 250 K | |
| Shares Float | 439.3 M |
Innovation Pharmaceuticals Fundamentals Growth
Innovation Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Innovation Pharmaceuticals, and Innovation Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Innovation Pink Sheet performance.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (339.83) % | |||
| Current Valuation | 7.56 M | |||
| Shares Outstanding | 488.32 M | |||
| Price To Earning | (7.57) X | |||
| Price To Book | 2.95 X | |||
| Price To Sales | 557.16 X | |||
| Revenue | 18 K | |||
| EBITDA | (6.54 M) | |||
| Cash And Equivalents | 2.97 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.24 M | |||
| Debt To Equity | 0.36 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (6.28 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 10.38 M | |||
| Retained Earnings | (87.38 M) | |||
| Current Asset | 529.15 K | |||
| Current Liabilities | 484.43 K | |||
About Innovation Pharmaceuticals Performance
Evaluating Innovation Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Innovation Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Innovation Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts. Innovation Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Innovation Pharmaceuticals performance evaluation
Checking the ongoing alerts about Innovation Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Innovation Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Innovation Pharmaceuticals is way too risky over 90 days horizon | |
| Innovation Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Innovation Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Innovation Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Innovation Pharmaceuticals currently holds 1.24 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Innovation Pharmaceuticals has a current ratio of 0.59, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation to invest in growth at high rates of return. When we think about Innovation Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 18 K. Net Loss for the year was (7.04 M) with profit before overhead, payroll, taxes, and interest of 18 K. | |
| Innovation Pharmaceuticals currently holds about 2.97 M in cash with (6.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Innovation Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Innovation Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Innovation Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Innovation Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Innovation Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Innovation Pharmaceuticals' pink sheet. These opinions can provide insight into Innovation Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Innovation Pink Sheet Analysis
When running Innovation Pharmaceuticals' price analysis, check to measure Innovation Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation Pharmaceuticals is operating at the current time. Most of Innovation Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Innovation Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation Pharmaceuticals' price. Additionally, you may evaluate how the addition of Innovation Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.